Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June:

• Jefferies 2017 Global Healthcare ConferencePresentation: Friday, June 9, 2017 at 9:30 a.m. Eastern TimeThe Grand Hyatt New York Hotel, New York, NY

• JMP Securities 2017 Life Sciences ConferencePanel Discussion: “Innovations in Ophthalmology”Tuesday, June 20, 2017 at 4:00 p.m. Eastern TimeThe St. Regis New York Hotel, New York, NY

A live audio webcast of the presentation at the Jefferies Healthcare Conference can be accessed through the Investors section of the Company's website at investors.ocutx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. The FDA has accepted the Company’s NDA resubmission for DEXTENZA for the treatment of ocular pain following ophthalmic surgery and has established a PDUFA target action date of July 19, 2017. If approved, the Company intends to submit a supplement to its NDA for ocular inflammation. OTX-TP (travoprost insert) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170601005160/en/

Media
Medical Dynamics
Sandra Correa, 646-599-8637
Business & Media Group Director
[email protected]
or
Investors
Burns McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
[email protected]
or
Ocular Therapeutix
Scott Corning
Vice President of Marketing & Commercial Operations
[email protected]

Source: Ocular Therapeutix, Inc.

You May Also Be Interested In

• FDA extends Exelixis zanzalintinib review by three months
• Ynvisible Advances Commercial Program with Sapphiros, Announces CFO Appointment and Adoption of Semi-Annual Financial Reporting
• Uaralyx Examines Post-Trade Verification Framework for Digital Asset Transparency